EIDD-2801
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555745

CAS#: 2349386-89-4

Description: Molnupiravir, also known as EIDD-2801 and MK-4482, is an orally bioavailable form of a highly potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. EIDD-2801 has been shown to improve pulmonary function, decrease body weight loss and reduce the amount of virus in the lung. In addition to activity against coronaviruses, EIDD-2801, in laboratory studies, has demonstrated activity against seasonal and bird influenza, respiratory syncytial virus, chikungunya virus, Ebola virus, Venezuelan equine encephalitis virus, and Eastern equine encephalitis virus. EIDD-2801 is a prodrug of EIDD-1931.

Chemical Structure

img
EIDD-2801
CAS# 2349386-89-4
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 555745
Name: EIDD-2801
CAS#: 2349386-89-4
Chemical Formula: C13H19N3O7
Exact Mass: 329.12
Molecular Weight: 329.310
Elemental Analysis: C, 47.42; H, 5.82; N, 12.76; O, 34.01

Price and Availability

Size Price Availability Quantity
100mg USD 150 Ready to ship
200mg USD 250 Ready to ship
500mg USD 400 Ready to ship
1g USD 550 Ready to ship
5g USD 950 Ready to ship
10g USD 1650 Ready to ship
20g USD 2950 Ready to ship
Bulk inquiry

Synonym: Molnupiravir; MK-4482; MK4482; MK 4482; EIDD-2801; EIDD 2801; EIDD2801; prodrug-EIDD-1931; prodrug-EIDD 1931; prodrug-EIDD1931.

IUPAC/Chemical Name: ((2R,3S,4R,5R)-3,4-dihydroxy-5-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate

InChi Key: HTNPEHXGEKVIHG-QCNRFFRDSA-N

InChi Code: InChI=1S/C13H19N3O7/c1-6(2)12(19)22-5-7-9(17)10(18)11(23-7)16-4-3-8(15-21)14-13(16)20/h3-4,6-7,9-11,17-18,21H,5H2,1-2H3,(H,14,15,20)/t7-,9-,10-,11-/m1/s1

SMILES Code: O[C@@H]([C@H]([C@H](N1C(N/C(C=C1)=N/O)=O)O2)O)[C@H]2COC(C(C)C)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target: Molnupiravir (EIDD-2801) is a bioavailable prodrug of the ribonucleoside analog EIDD-1931 that has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV.
In vitro activity: Molnupiravir is a broad-spectrum antiviral that is an orally bioavailable prodrug of the nucleoside analogue β-D-N4-hydroxycytidine (NHC). Molnupiravir or NHC can increase G to A and C to U transition mutations in replicating coronaviruses. These increases in mutation frequencies can be linked to increases in antiviral effects. Here, the effects of the active compound NHC 5'-triphosphate (NHC-TP) against the purified severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase complex were studied. The efficiency of incorporation of natural nucleotides over the efficiency of incorporation of NHC-TP into model RNA substrates followed the order GTP (12,841) > ATP (424) > UTP (171) > CTP (30), indicating that NHC-TP competes predominantly with CTP for incorporation. No significant inhibition of RNA synthesis was noted as a result of the incorporated monophosphate in the RNA primer strand. When embedded in the template strand, NHC-monophosphate supported the formation of both NHC:G and NHC:A base pairs with similar efficiencies. The extension of the NHC:G product was modestly inhibited, but higher nucleotide concentrations could overcome this blockage. In contrast, the NHC:A base pair led to the observed G to A (G:NHC:A) or C to U (C:G:NHC:A:U) mutations. Together, these biochemical data support a mechanism of action of molnupiravir that is primarily based on RNA mutagenesis mediated via the template strand. Reference: J Biol Chem. 2021 Jul; 297(1): 100770. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110631/
In vivo activity: The efficacy of the MK-4482 prodrug was next assessed in the Syrian hamster model, which is regarded as a preclinical model of mild disease, with animals having self-limiting pneumonia.. Given the possibility for oral dosing, the utility of MK-4482 as a treatment following high-risk exposure was inspected. Two groups of hamsters (n = 6 per group) were treated with MK-4482 (250 mg/kg) by oral gavage 12 h and 2 h before (pre-infection treatment group) or 12 h post-infection (post-infection treatment group). Lung tissue samples were collected at the peak of virus replication and disease, day 4 post-infection, for analysis. In contrast to levels of shedding, a 1-log decrease in viral RNA was detected in the lungs of pre-infection and post-infection groups, respectively, when compared to the vehicle control group (Fig. 2d). This corresponded to a 2-log decrease in infectious virus in the lungs of the MK-4482 treated groups when compared to the vehicle controls (Fig. 2e). MK-4482 was not detected in the tissue. Then compared to the vehicle, viral genomes from MK-4482 treated animals had a significant accumulation of nucleotide substitutions (Supplementary Table 2). Together, these results are consistent with the RNA mutagenesis function of MK-4482 in the reduction of infectious virus and disease in treated animals. If adequately priced for widespread global use, MK-4482 should be considered as an oral postexposure application for SARS-CoV-2. Reference: Nat Commun. 2021; 12: 2295. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052374/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 100.0 303.67
DMF 50.0 151.83

Preparing Stock Solutions

The following data is based on the product molecular weight 329.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem. 2021 May 11;297(1):100770. doi: 10.1016/j.jbc.2021.100770. Epub ahead of print. PMID: 33989635; PMCID: PMC8110631. 2. Rosenke K, Hansen F, Schwarz B, Feldmann F, Haddock E, Rosenke R, Barbian K, Meade-White K, Okumura A, Leventhal S, Hawman DW, Ricotta E, Bosio CM, Martens C, Saturday G, Feldmann H, Jarvis MA. Orally delivered MK-4482 inhibits SARSCoV-2 replication in the Syrian hamster model. Nat Commun. 2021 Apr 16;12(1):2295. doi: 10.1038/s41467-021-22580-8. PMID: 33863887; PMCID: PMC8052374. 3. Cox RM, Wolf JD, Plemper RK. Therapeutic MK-4482/EIDD-2801 Blocks SARS-CoV-2 Transmission in Ferrets. Res Sq [Preprint]. 2020 Oct 12:rs.3.rs-89433. doi: 10.21203/rs.3.rs-89433/v1. Update in: Nat Microbiol. 2020 Dec 3;: PMID: 33052328; PMCID: PMC7553152.
In vitro protocol: 1. Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem. 2021 May 11;297(1):100770. doi: 10.1016/j.jbc.2021.100770. Epub ahead of print. PMID: 33989635; PMCID: PMC8110631. 2. Rosenke K, Hansen F, Schwarz B, Feldmann F, Haddock E, Rosenke R, Barbian K, Meade-White K, Okumura A, Leventhal S, Hawman DW, Ricotta E, Bosio CM, Martens C, Saturday G, Feldmann H, Jarvis MA. Orally delivered MK-4482 inhibits SARSCoV-2 replication in the Syrian hamster model. Nat Commun. 2021 Apr 16;12(1):2295. doi: 10.1038/s41467-021-22580-8. PMID: 33863887; PMCID: PMC8052374.
In vivo protocol: 1. Cox RM, Wolf JD, Plemper RK. Therapeutic MK-4482/EIDD-2801 Blocks SARS-CoV-2 Transmission in Ferrets. Res Sq [Preprint]. 2020 Oct 12:rs.3.rs-89433. doi: 10.21203/rs.3.rs-89433/v1. Update in: Nat Microbiol. 2020 Dec 3;: PMID: 33052328; PMCID: PMC7553152. 2. Rosenke K, Hansen F, Schwarz B, Feldmann F, Haddock E, Rosenke R, Barbian K, Meade-White K, Okumura A, Leventhal S, Hawman DW, Ricotta E, Bosio CM, Martens C, Saturday G, Feldmann H, Jarvis MA. Orally delivered MK-4482 inhibits SARSCoV-2 replication in the Syrian hamster model. Nat Commun. 2021 Apr 16;12(1):2295. doi: 10.1038/s41467-021-22580-8. PMID: 33863887; PMCID: PMC8052374.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Schäfer A, Dinnon KH 3rd, Stevens LJ, Chappell JD, Lu X, Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR, Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ, Swanstrom R, Denison MR, Baric RS. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 6:eabb5883. doi: 10.1126/scitranslmed.abb5883. Epub ahead of print. PMID: 32253226.


2: Hampton T. New Flu Antiviral Candidate May Thwart Drug Resistance. JAMA. 2020 Jan 7;323(1):17. doi: 10.1001/jama.2019.20225. PMID: 31910262.


3: Toots M, Yoon JJ, Hart M, Natchus MG, Painter GR, Plemper RK. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Transl Res. 2020 Apr;218:16-28. doi: 10.1016/j.trsl.2019.12.002. Epub 2019 Dec 25. PMID: 31945316.


4: Toots M, Yoon JJ, Cox RM, Hart M, Sticher ZM, Makhsous N, Plesker R, Barrena AH, Reddy PG, Mitchell DG, Shean RC, Bluemling GR, Kolykhalov AA, Greninger AL, Natchus MG, Painter GR, Plemper RK. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11(515):eaax5866. doi: 10.1126/scitranslmed.aax5866. PMID: 31645453; PMCID: PMC6848974.


5: Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019 Jul;167:45-67. doi: 10.1016/j.antiviral.2019.04.006. Epub 2019 Apr 8. PMID: 30974127; PMCID: PMC7132446.